Stockreport

Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate

IPSEN SA S/ADR  (IPSEY) 
NASDAQ:AMEX Investor Relations: ipsen.com/investors
PDF Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a LRRC15-targeting antibody-drug conjugat [Read more]